HIV-1 Infections Clinical Trial
Official title:
HIV Pre-Exposure Prophylaxis Priming of Immune Effectors
Can HIV-specific immunity develop in HIV uninfected humans exposed to HIV whilst receiving antiretroviral pre-exposure prophylaxis (PrEP)? Investigators will investigate this possibility in commercial sex workers in Kampala who will be receiving Truvada PrEP for one year.
Design This will be a single centre open label longitudinal observational trial. Women
attending the "Good Health for Women" clinic will be informed about the objectives of the
trial and volunteers able to provide informed consent and with high risk of exposure to HIV-1
determined by a sexual history questionnaire will be screened by Rapid antibody test.
Seronegatives will be checked for eligibility by clinical examination and laboratory tests.
The endpoint for enrolment will be 220 uninfected high risk participants.
Baseline blood samples will be obtained from participants at month 0. A monthly diary card
will be provided for self documenting sexual exposure, alcohol use and pill taking.
Participants will receive provisions of PrEP (tenofovir disoproxil fumarate (TDF) and
emtricitabine (FTC) sufficient for one month, will be instructed on the daily prophylaxis and
on how to record adherence on the diary card. Participants will be asked to return each month
for treatment re-provisioning and a new card. The content of the diary card will be discussed
in a short interview each month.
At month 6 and 12 blood samples will be collected for evaluating immune responses to HIV-1.
Additional tests will be done for monitoring HIV-1 status, pregnancy and sexually transmitted
infections (STIs). After month 12 PrEP will be discontinued (unless participants opt to
continue PrEP until the end of the follow up) and all participants will provide blood samples
at month 18.
Baseline and follow-up peripheral blood mononuclear cells (PBMC) samples will be compared for
T cell responses to HIV by interferon-γ (IFN-γ) enzyme-linked immunospot (ELISPOT). In case
of a positive immune response, plasma collected at the same time point will be nucleic acid
test (NAT) tested to verify absence of HIV infection.
HIV infected participants will be evaluated for cluster of differentiation 4 (CD4) T cells
and viral load and referred to a Care Program (PEPFAR).
At month 6, 12 and 18 in-depth interviews will be conducted with a randomly selected sample
of 44 women (20 percent) to discuss facilitators and barriers to adherence. The diary answers
will be tabulated to look for patterns and trends. A framework approach to analysis will be
used for the analysis of the qualitative data from interviews.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01013415 -
CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients
|
Phase 1 | |
| Active, not recruiting |
NCT02923713 -
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
|
Phase 2 | |
| Completed |
NCT01151319 -
Safety and Immunogenicity Study of Three Candidate HIV-1 Vaccines, Administered in Combination to Healthy HIV-1 Uninfected Adults
|
Phase 1 | |
| Completed |
NCT01138605 -
TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV
|
Phase 2 | |
| Completed |
NCT01078233 -
Observational Data Analysis in EuroSIDA (MK-0518-058)
|
||
| Completed |
NCT00557245 -
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples
|
Phase 3 | |
| Withdrawn |
NCT00984152 -
Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
|
Phase 3 | |
| Completed |
NCT00799058 -
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States
|
Phase 1/Phase 2 | |
| Completed |
NCT01159275 -
Lopinavir (LPV) Dose Reduction
|
Phase 1/Phase 2 | |
| Completed |
NCT01281813 -
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
|
Phase 3 | |
| Completed |
NCT01078246 -
Post-Licensure Safety Study of ISENTRESS™ (Raltegravir) in a United States Managed Care Network (MK-0518-268)
|
||
| Active, not recruiting |
NCT03027297 -
TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRV
|
Phase 3 | |
| Completed |
NCT01139905 -
Lopinavir/Ritonavir (LPV/r) Tablet in HIV Infected Children
|
Phase 2 | |
| Completed |
NCT01033760 -
Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)
|
Phase 3 | |
| Completed |
NCT00830804 -
Safety and Effectiveness of Raltegravir Plus Darunavir/Ritonavir in Treatment-Naive HIV-Infected Adults
|
Phase 2 | |
| Completed |
NCT01074931 -
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
|
N/A |